TY - JOUR
T1 - Acute electrophysiologic effects of an HT2-serotonin antagonist, ketanserin, in humans
AU - Kaye, G. C.
AU - Mehta, D.
AU - Wafa, S.
AU - Camm, A. J.
PY - 1990/8
Y1 - 1990/8
N2 - The acute electrophysiologic effects of an intravenous bolus of ketanserin, a 5HT2 serotonin blocker, were studied in ten patients (four females, six males) during invasive electrophysiology. Following baseline electrophysiologic measurements during sinus rhythm and fixed-rate atrial pacing at 600 ms, a bolus of 0.2 mg/kg ketanserin was given over a 3-minute period. After 30 minutes all measurements were repeated. Systemic blood pressure was measured at regular intervals throughout. During sinus rhythm, there was no significant change in the basic cycle length or in the PA, AH, HV, QRS, QT, and QTc intervals. During atrial pacing there was a nonsignificant increase in the QT interval, from 342±13 ms to 366±16 ms, and a significant increase in the QTc interval, from 422±27 ms to 449±29 ms (p<0.05). There was no reduction in blood pressure. Thus ketanserin produced a significant prolongation of the QTc interval, in the absence of hypokalemia, in humans.
AB - The acute electrophysiologic effects of an intravenous bolus of ketanserin, a 5HT2 serotonin blocker, were studied in ten patients (four females, six males) during invasive electrophysiology. Following baseline electrophysiologic measurements during sinus rhythm and fixed-rate atrial pacing at 600 ms, a bolus of 0.2 mg/kg ketanserin was given over a 3-minute period. After 30 minutes all measurements were repeated. Systemic blood pressure was measured at regular intervals throughout. During sinus rhythm, there was no significant change in the basic cycle length or in the PA, AH, HV, QRS, QT, and QTc intervals. During atrial pacing there was a nonsignificant increase in the QT interval, from 342±13 ms to 366±16 ms, and a significant increase in the QTc interval, from 422±27 ms to 449±29 ms (p<0.05). There was no reduction in blood pressure. Thus ketanserin produced a significant prolongation of the QTc interval, in the absence of hypokalemia, in humans.
KW - QT interval
KW - QTc interval
KW - ketanserin
KW - serotonin antagonist
UR - http://www.scopus.com/inward/record.url?scp=0025028718&partnerID=8YFLogxK
U2 - 10.1007/BF01856513
DO - 10.1007/BF01856513
M3 - Article
C2 - 2083196
AN - SCOPUS:0025028718
SN - 0920-3206
VL - 4
SP - 1157
EP - 1160
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 4
ER -